Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

Ann Transl Med. 2020 Dec;8(23):1611. doi: 10.21037/atm-20-2656.
No abstract available

Publication types

  • Editorial
  • Comment